POC HIV Testing and Early DTG Use for Infants

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

July 4, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

August 31, 2026

Conditions
HIV
Interventions
DIAGNOSTIC_TEST

Point-of-Care Cepheid Xpert HIV-1

Post-partum HIV-positive women with pre-determined risk factors for vertical HIV transmission will be offered point-of-care HIV testing for their newborns for early infant HIV diagnosis.

DRUG

DTG/ABC/3TC

Infants will be started on a combination of NVP/ZDV/3TC. A switch to DTG/ABC/3TC will occur for all infants at or after 4 weeks (28 days) post-delivery for those weighing ≥3kg. Dosing of all ART will be weight-based by the Botswana treatment guidelines.

Trial Locations (1)

Unknown

Botswana Harvard HIV/AIDS Institute Partnership, Gaborone

All Listed Sponsors
collaborator

Botswana Harvard AIDS Institute Partnership

OTHER

collaborator

Ragon Institute of MGH, MIT and Harvard

OTHER

collaborator

Botswana Ministry of Health

OTHER_GOV

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Harvard School of Public Health (HSPH)

OTHER